Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 4 Mar 2009 |
| Orion: Primary objective of STRIDE-PD study was not achieved | 24 Feb 2009 |
| Orion Group Financial Review of 2008 | 6 Feb 2009 |
| Matters to be handled at the AGM of Orion Corporation on 23 March 2009 | 6 Feb 2009 |
| Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2009 AGM of Orion Corporation | 28 Jan 2009 |